The Allogeneic Future with Poseida's Kristin Yarema, Ph.D.
Business Of Biotech - Podcast autorstwa Matt Pillar - Poniedziałki
Kategorie:
We love to hear from our listeners. Send us a message. Kristin Yarema, Ph.D. thinks the progress of CAR T therapeutics is allogeneic. In fact, she says CAR T-cell therapies have to become a one-to-many proposition, if their early autologous success can possibly live up to the promise of offering widespread accessibility to life-saving treatments. Dr. Yarema is the newly-appointed CEO at Poseida Therapeutics, a company we first covered with founding CEO Eric Ostertag, Ph.D. On this episode of ...
